Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a
clinical stage biotechnology company developing regenerated organs for
transplant, initially focused on the trachea, was spotlighted in an
article published by Investor’s Business Daily on February 3.
The article, “Picking Your People Portfolio? Find Giants And Guides,”
focuses on the role of “inspirational giants” in driving business
success. David Green, CEO of Harvard Apparatus Regenerative Technology,
cites the late South African President Nelson Mandela as his personal
inspiration. The article notes that Mr. Green met Mr. Mandela when
working as a consultant with Cambridge, MA-based Monitor Co. in South
Africa in the early 1990s, and advised the newly democratic
post-apartheid government on industrial policy while living there.
To read the article in its entirety, please visit the following link:
http://news.investors.com/management-leaders-in-success/020314-688606-choose-advisers-who-inspire-your-goals.htm?p=full
About Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology makes regenerated organs for
transplant. Our first product, the InBreathTM Airway
Transplant System, is intended to replace or repair a trachea that has
been severely damaged by either trachea cancer or physical trauma. Our
technology has been used in eight human trachea transplants to date
approved under compassionate use exemptions, but none of our products
are yet approved by a government regulatory authority for marketing. On
November 1, 2013, HART was spun-off from Harvard Bioscience. The
trademark “Harvard Apparatus” is used under a sublicense agreement with
Harvard Bioscience, who has licensed the right to use such trademark
from Harvard University.
Forward-Looking Statements
Some of the statements in this press release are "forward-looking" and
are made pursuant to the safe harbor provision of the Private Securities
Litigation Reform Act of 1995. These "forward-looking" statements
include statements relating to, among other things, the planned
commercialization efforts and marketing approvals of HART’s products as
well as the success thereof and the availability of a market for the
HART securities. These statements involve risks and uncertainties,
including among other things, market conditions that may cause results
to differ materially from the statements set forth in this press
release. The forward-looking statements in this press release speak only
as of the date of this press release. Harvard Apparatus Regenerative
Technology expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to such statements to reflect any
change in its expectations with regard thereto or any changes in the
events, conditions or circumstances on which any such statement is based.
Copyright Business Wire 2014